CHADDS FORD, Pa., Feb. 9, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) will announce its fourth quarter and full-year 2010 financial results on February 28, 2011 and will host a conference call and webcast at 10:00 a.m. ET that day to discuss these results.
David P. Holveck, president and CEO of Endo, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, Alan Levin, executive vice president and chief financial officer and Blaine Davis, vice president, corporate affairs will host the call.
Investors and other interested parties may call 866-543-6407 (domestic) or 617-213-8898 (international) and enter passcode 52703236. Please dial in 10 minutes prior to the scheduled start time.
A replay of the call will be available from February 28 at 1:00 p.m. ET until 12:00 a.m. ET on March 8 by dialing 888-286-8010(domestic) or 617-801-6888(international) and entering passcode 27142919.
A simultaneous webcast of the call may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until 12:00 a.m. ET on March 8. The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.
Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit www.endo.com.
SOURCE Endo Pharmaceuticals